Literature DB >> 26542597

Exacerbations of Chronic Obstructive Pulmonary Disease and Quality of Life of Patients.

R Rubinsztajn, T Przybyłowski, M Maskey-Warzechowska, K Karwat, R Chazan.   

Abstract

Exacerbations of chronic obstructive pulmonary disease (COPD) are one of the most important factors which influence the course of disease and quality of life in COPD patients. The aim of the study was to assess the exacerbation frequency in COPD patients in relation to COPD severity and to evaluate the impact of the number of exacerbations on quality of life. The study included 445 COPD patients in all four progressive stages of the disease according to GOLD classification. The patients recorded exacerbations in diaries. Spirometry, St. George's Respiratory Questionnaire, and dyspnea score were assessed at baseline and after 12 and 24 months from enrollment. After 24 months, 261 diaries were returned. The mean number of exacerbations per year in the sequential GOLD 1-4 stages of COPD was as follows: 1.3 ± 2.1, 1.4 ± 2.0, 1.7 ± 1.8, and 3.4 ± 4.5. A statistical difference in the exacerbation frequency was noted for GOLD 4 and the remaining groups. A significant negative correlation was found between the number of exacerbations and functional status for GOLD 2 and 3 stages. We conclude that the number of exacerbations is the highest in the most severe stage of the disease. The quality of life of patients with moderate and severe COPD correlates negatively with the number of exacerbations.

Entities:  

Mesh:

Year:  2016        PMID: 26542597     DOI: 10.1007/5584_2015_178

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  6 in total

1.  Nutrition as a modifiable factor in the onset and progression of pulmonary function impairment in COPD: a systematic review.

Authors:  Lieke E J van Iersel; Rosanne J H C G Beijers; Harry R Gosker; Annemie M W J Schols
Journal:  Nutr Rev       Date:  2022-05-09       Impact factor: 6.846

2.  Gallic acid ameliorates COPD-associated exacerbation in mice.

Authors:  Esha Singla; Gayatri Puri; Vivek Dharwal; Amarjit S Naura
Journal:  Mol Cell Biochem       Date:  2020-09-23       Impact factor: 3.396

3.  Relative impact of COPD and comorbidities on generic health-related quality of life: a pooled analysis of the COSYCONET patient cohort and control subjects from the KORA and SHIP studies.

Authors:  Margarethe E Wacker; Rudolf A Jörres; Annika Karch; Armin Koch; Joachim Heinrich; Stefan Karrasch; Holger Schulz; Annette Peters; Sven Gläser; Ralf Ewert; Sebastian E Baumeister; Claus Vogelmeier; Reiner Leidl; Rolf Holle
Journal:  Respir Res       Date:  2016-07-12

4.  Assessing the Usefulness of the Prevexair Smartphone Application in the Follow-Up High-Risk Patients with COPD.

Authors:  Juan Luis Rodríguez Hermosa; Antonia Fuster Gomila; Luis Puente Maestu; Carlos Antonio Amado Diago; Francisco Javier Callejas González; Rosa Malo De Molina Ruiz; Manuel E Fuentes Ferrer; Jose Luis Alvarez-Sala; Myriam Calle Rubio
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-01-08

5.  Effect of periodontal therapy on COPD outcomes: a systematic review.

Authors:  Ioulianos Apessos; Athanasios Voulgaris; Michalis Agrafiotis; Dimitrios Andreadis; Paschalis Steiropoulos
Journal:  BMC Pulm Med       Date:  2021-03-18       Impact factor: 3.317

6.  Prediction of gold stage in patients hospitalized with COPD exacerbations using blood neutrophils and demographic parameters as risk factors.

Authors:  Jing Chen; Zhao Yang; Qun Yuan; Li-Quan Guo; Da-Xi Xiong
Journal:  BMC Pulm Med       Date:  2021-10-21       Impact factor: 3.317

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.